- Dannis G. van Vuurden MD, MSc, & Esther Hulleman, VU Cancer Center Amsterdam, and
- Jacques Grill, Institut Gustave-Roussy, Villejuif, France
The ultimate goal is to move the most effective single agent or combination therapy forward to early phase clinical trials in the next 18-24 months. This is the first time that a group of basic and translational scientists and physicians from eight institutions throughout North America and Europe have come together as a consortium to focus on DIPGs and to focus on a bench-to-bedside approach to rationally target therapy for children with DIPGs.
For the Open Science Forum week to week update of this project, click here.